Background: Proton pump inhibitors (PPI) are widely used for the treatment of gastric acid-related disease, but they are not approved for use in children in Japan. To assess the safety, pharmacokinetics, pharmacodynamics, and efficacy (gastrointestinal symptom improvement) of PPI in Japanese pediatric patients with gastric acid-related disease, we conducted an 8 week, open-label, parallel-group, multicenter, phase I/III study of once-daily oral esomeprazole use. Methods: Japanese children, aged 1-14 years with gastric acid-related disease, were stratified by weight and age into five groups (10 patients/group) to receive esomeprazole as granules for suspension (10 mg) or capsules (10 mg or 20 mg) once daily.
only in Japan based on studies demonstrating a strong gastric anti-secretory activity 10 and high rates of healing in reflux esophagitis (RE; 87.3%). 11 There is no PPI currently approved for use in children in Japan. The present study investigated the safety, tolerability, clinical efficacy, pharmacokinetics (PK), and pharmacodynamics (PD) of esomeprazole in Japanese pediatric patients with gastric acid-related disease.
Methods

Patients
Study inclusion criteria were as follows: Japanese ethnicity; age, 1-14 years; weight, >10 kg; body mass index 3rd-97th percentile; and confirmed or suspected diagnosis of gastric ulcer (GU), duodenal ulcer (DU), anastomotic ulcer (AU), non-erosive reflux disease (NERD), RE, or Zollinger-Ellison syndrome, based on upper GI endoscopy, pH monitoring, and/ or clinical symptoms.
Patients were excluded if they had been significantly ill or had taken any PPI in the last 4 weeks. Patients who had a condition deemed to interfere with the study, had allergy to PPI, or a requirement for medication that could interact with esomeprazole were also excluded. Patients were free to withdraw from the study at any time, or could be withdrawn by their guardians or the investigators.
Ethics approval
The study was conducted in accordance with the ethics principles of the Declaration of Helsinki, the International Conference on Harmonization Good Clinical Practice guidelines, Good Clinical Practice for Trials on Drugs (Ministry of Healthy, Labor and Welfare (MHLW) Ordinance No. 28, 27 March 1997), and applicable regulatory requirements. Written, informed consent was obtained from the guardians of all patients before enrolment in the study. Additional consent was obtained for intragastric pH monitoring and esophagogastroduodenoscopy (EGD). The study protocol was approved by the institutional review board at each participating site. The study was registered at ClinicalTrials.gov (NCT02153398). This open-label, parallel-group, combined phase I/III clinical study was conducted to determine the safety and efficacy of esomeprazole in Japanese pediatric patients with gastric acidrelated disease. The study involved five scheduled visits: enrolment; registration; and visits after 1, 4, and 8 weeks of dosing. PK and upper GI symptoms were assessed in all patients but intragastric pH and EGD were performed only in the subset of patients who gave consent for these investigations.
The patients were allocated to five groups based on age and bodyweight, to receive esomeprazole for 8 weeks. Patients <20 kg were allocated to group 1 and received a 10 mg esomeprazole sachet daily. Patients ≥20 kg were randomized to groups 2-5, based on their age (1-11 or 12-14 years old) and given either 10 mg (groups 2 and 4) or 20 mg (groups 3 and 5) esomeprazole once daily in capsule form (Fig. 1) . The sample size was based on feasibility to include at least 10 each in groups 2-5 (i.e. 40 patients in total), and 5-10 patients in group 1.
The esomeprazole doses in this study were based on US/ EU approved doses and on PK, safety and clinical data from previous pediatric studies in Caucasian subjects that demonstrated relevant exposure following 10 and 20 mg, but too low exposure following a dose of 5 mg. [12] [13] [14] [15] [16] Bioequivalence has previously been demonstrated between esomeprazole given as sachets (granules for suspension) and capsules (Dr Helen Lunde, unpubl. data, 2014).
Safety and tolerability
Safety and tolerability were evaluated on adverse events (AE), physical examination, vital signs, and clinical laboratory tests. AE were recorded from registration until last visit or withdrawal. Serious AE (SAE), however, were recorded from the time of informed consent, at enrolment. Blood and urine samples for clinical chemistry, hematology, and urinalysis were collected after ≥4 h of fasting. All patients who received at least one dose of esomeprazole and had any post-dose data were included in the safety analysis.
Upper GI symptoms
The intensity of the upper GI symptoms, that is, heartburn, epigastric pain, upper abdominal discomfort, and regurgitation, were recorded at baseline and then daily during treatment by the patient/guardians, and at baseline and after 1, 4, and 8 weeks of treatment by the investigators. Baseline recording was performed at registration, based on a 7 day retrospective evaluation. Symptom intensity was scored as 0, no symptoms, "none"; 1, easily tolerated, "mild"; 2, interference with normal activities, "moderate";, and 3, not able to perform normal activities, "severe".
Pharmacokinetics, Helicobacter pylori
Pharmacokinetic evaluation was performed after ≥5 days of repeated dosing, with participants fasted for ≥4 h before and until 1 h after dosing. Blood sampling was performed 30 min before (trough concentration) and 30, 60, 90, 120, 180, 240, and 360 min after dosing. Blood samples were spun at ≥2,0009 g for 20 min at 4°C to obtain plasma samples and stored at ≤À20°C until analyzed using a validated bioanalytical method by Covance Laboratories Limited (Harrogate, UK).
The following PK variables were analyzed: area under the plasma concentration-time curve (AUC) during a dosage interval (AUC tau ); AUC from time zero to time t (AUC 0-t ); maximum plasma drug concentration (C max ); time to reach maximum plasma concentration (t max ); terminal elimination half-life (t 1/2 ); apparent total body clearance (CL/F); and apparent volume of distribution during terminal phase after non-i.v. administration (V z /F).
The PK variables of 5-hydroxy and sulfone metabolites of esomeprazole were also assessed and included AUC tau , AUC 0-t , C max , t max , and t 1/2 . Concentration-time data were analyzed using a non-compartmental approach with WinNonlin Enterprise Edition version 5.2.1 (Pharsight, MountainView, CA, USA). The PK data analysis set included all patients who had at least one recorded plasma concentration after dosing and had no protocol deviations with impact on the PK.
Blood sampling for genotyping of CYP2C19, encoding a metabolizing enzyme of esomeprazole, was, after informed consent, obtained from all participants at enrolment Genetic testing was conducted by LSI Medience (Tokyo, Japan). CYP2C19 single-nucleotide polymorphisms (SNP) resulting in point mutations of 681G>A (*2) and 636G>A (*3) were detected and the SNP genotypes were translated into star-allele genotypes. The patients were classified as homo-extensive metabolizers (homo-EM) (*1/*1), hetero-EM (*1/*2, *1/*3) and poor metabolizers (PM) (*2/*2, *2/*3, *3/*3). All patients were tested for H. pylori immunoglobulin G antibodies in the blood, according to each institution's standard method.
Intragastric pH, EGD
Intragastric pH monitoring, to assess PD of esomeprazole, was performed at baseline (data not demonstrated) and after ≥5 days of repeated dosing in the subgroup of patients who gave consent for this investigation. The participants fasted for ≥4 h before pH monitoring, a standardized diet with a pH between 5 and 7 was given during the test period. A nasal pH probe was inserted into the stomach and location confirmed on X-ray. Intragastric pH was recorded every 10 s for 12 h. The PD analysis set included all patients who had baseline and post-baseline PD data without any protocol deviations with impact on the PD. The percentage of time with intragastric pH >4 and >3, and the median intragastric pH for 12 h were analyzed. EGD assessment was performed in patients who gave consent for this evaluation, at baseline (including EDG in the 2 weeks before registration) and if clinically indicated during the treatment period.
Statistical analysis
Clinical laboratory data and vital signs are presented by treatment group as descriptive statistics for count, mean, standard deviation, maximum, median, and minimum at baseline and subsequent visits, and changes from baseline. Qualitative data are summarized for each treatment by frequency and percentage. Changes from baseline to last visit are presented in shift tables showing distribution of patients with values below and above the reference range compared with pre-and post-treatment values. Baseline values were from visit 1, and for clinical laboratory data and vital signs at visit 2.
No hypothesis tests were used, a two-sided 0.05 level of significance was used for assessing confidence intervals. All statistical analyses were performed using SAS version 9.3 (SAS Institute, Cary, NC, USA).
Results
Patients
Fifty-five patients were screened, of whom 50 (female, 52%) were eligible and registered in the study into five treatment groups (10 patients per group); all registered patients received esomeprazole, and 47 completed the study; one discontinued due to an AE and two due to withdrawal of consent. Median exposure to esomeprazole was similar in the five groups, and ranged across the groups from 55.0 days to 56.5 days.
The most frequently reported eligible diseases were NERD, with six patients each (60%) in groups 1, 3, and 4; RE, with five patients (50%) in group 2; and GU, with five patients (50%) in group 5. Some patients had more than one diagnosis. In total, five patients (10%) tested positive for H. pylori, two in group 1, and one each in groups 2, 3, and 5. For the CYP2C19 genotype, 29 patients (58.0%), 14 patients (28.0%) and seven patients (14.0%) were hetero-EM, homo-EM, and PM genotype, respectively (Table 1) .
Safety and tolerability
Of the 50 patients assessed for safety, 33 patients (66.0%) reported one or more AE during the study period, nasopharyngitis (22.0%) being the most frequent ( Table 2 ). The AE were scored as mild/moderate in 31/33 patients. Three events (abdominal pain, diarrhea, and photosensitivity reaction) in two patients (4.0%) were judged to be causally related to esomeprazole. Although no causality of esomeprazole was reported, three patients (two in group 1 and one in group 5) had one SAE each (anaphylactic reaction to milk, irritable bowel syndrome, and aggravation of known asthma, the latter [group 1] leading to withdrawal of consent). Esomeprazole was discontinued in one patient in group 3 due to AE (abdominal pain and diarrhea). There were no deaths during the study period.
No clinically relevant trends were observed during the study in either blood or urine laboratory or physical examinations.
Upper GI symptoms
Upper GI symptoms were recorded in all 50 patients, with approximately half of the patients having upper GI symptoms Some subjects had overlapping diagnoses of gastric ulcer, duodenal ulcer, NERD, and reflux esophagitis. Group 1, age ≥1 year, weight <20 kg, esomeprazole sachet 10 mg; group 2, age 1-11 years, weight ≥20 kg, esomeprazole capsule 10 mg; group 3, age 1-11 years, weight ≥20 kg, esomeprazole capsule 20 mg; group 4, age 12-14 years, weight ≥20 kg, esomeprazole capsule 10 mg; group 5, age 12-14 years, weight ≥20 kg, esomeprazole capsule 20 mg. EM, extensive metabolizer; NERD, non-erosive reflux disease; PM, poor metabolizer. Group 1, age ≥1 year, weight <20 kg, esomeprazole sachet 10 mg; group 2, age 1-11 years, weight ≥20 kg, esomeprazole capsule 10 mg; group 3, age 1-11 years, weight ≥20 kg, esomeprazole capsule 20 mg; group 4, age 12-14 years, weight ≥20 kg, esomeprazole capsule 10 mg; group 5, age 12-14 years, weight ≥20 kg, esomeprazole capsule 20 mg.
at baseline (time of registration). In patients who had any symptoms at baseline, however, most patients (in all groups) became asymptomatic and reached sustained resolution (7 consecutive days free of symptoms) for all symptoms at the end of the study (Table 3 ). The investigator assessments of upper GI symptoms were generally in line with those recorded by the patients/guardians (data not shown).
Pharmacokinetics
Pharmacokinetics were analyzed in all registered patients, except for two patients for whom no blood samples were obtained (n = 48). The PK variables and plasma concentration-time curves obtained for esomeprazole are summarized in Table 4 and Figure 2 , respectively.
Esomeprazole was absorbed and eliminated rapidly in all groups, with a median t max of 1.47-1.75 h, an arithmetic mean t 1/2 of 0.80-1.37 h, and a weight-correlated CL/F of 0.216-0.343 L/h/kg. Even if high inter-individual variability was observed, in general, the AUC tau and C max were greater at the higher dose (20 mg) in patients with lower age and weight.
As expected, geometric mean for exposure was highest in patients lacking CYP2C19 activity (PM), whereas the lowest mean exposure was observed in patients with the highest activity of CYP2C19 (homo-EM). Due to high inter-individual variability, however, some PM patients had lower exposure than EM patients in the same dosing group (Table 4) .
The ratio of hydroxy and sulfone metabolite to esomeprazole for AUC tau and C max were in line with and confirmed the total AUC tau and C max results for the different CYP2C19 genotyping groups (Table 5) .
Intragastric pH
In this study, intragastric pH analysis was done in a subgroup of five patients who consented to this evaluation and for whom PD data were made available (two in group 2 and group 3, one in group 5). After ≥ 5 days of esomeprazole dosing, the percentage of time with intragastric pH >4 was from 51.2% to 98.3% and the percentage of time with intragastric pH >3 was from 65.4% to 99.0%.
Endoscopy
Esophagogastroduodenoscopy was performed in a subgroup of 14 patients who consented to this evaluation. At baseline, two patients were identified to have DU and one, RE on endoscopy; all resolved after esomeprazole treatment. Lesions were not detected on endoscopy at baseline in the other 11 patients. Of these, 10 patients were comprehensively Group 1, age ≥1 year, weight <20 kg, esomeprazole sachet 10 mg; group 2: age 1-11 years, weight ≥20 kg, esomeprazole capsule 10 mg; group 3, age 1-11 years, weight ≥20 kg, esomeprazole capsule 20 mg; group 4, age 12-14 years, weight ≥20 kg, esomeprazole capsule 10 mg; group 5, age 12-14 years, weight ≥20 kg, esomeprazole capsule 20 mg. FAS, full-analysis set; GI, gastrointestinal. diagnosed with NERD, and one with DU, based on endoscopy performed before registration and the development of clinical symptoms.
Discussion
This is the first study examining the effect of esomeprazole on safety and tolerability, clinical efficacy, PK, and PD in Japanese pediatric patients aged 1-14 years with gastric acidrelated disease.
In general, the AE reported were low in intensity and had a frequency in line with expectations. Two patients had mild/moderate AE judged to be causally related to the study drug, and three patients had SAE not causally related to the study drug.
The safety of 10 or 20 mg esomeprazole, given once daily as capsules or sachets for 8 weeks, was considered acceptable for all study groups and in line with the safety profile from previous studies in Caucasian children and in Japanese adults. [10] [11] [12] [13] [14] [15] Score of upper GI symptoms was collected throughout the study. Even if a limited number of patients reported symptoms during 7 days preceding the registration visit, most patients who reported symptoms at baseline became asymptomatic during treatment. Almost all patients had no or only mild symptoms at the end of the study, which was generally consistent with previous studies in Caucasian children. 12, 13 Three patients with endoscopically verified DU or RE at baseline had complete resolution following treatment with esomeprazole. Even if limited, however, these clinical findings suggest that esomeprazole has a clinically beneficial effect in Japanese children, as has been demonstrated in adult Japanese 10, 11 and Western pediatric patients.
12,13
The PK variables for esomeprazole indicated rapid absorption and elimination in Japanese children. The inter-individual variabilities in exposure were high even in the same age/weight/ dose groups. Mean plasma concentration was higher in younger children, but the increase in CL/F seen in younger patients disappeared when normalized to bodyweight. In general, the exposure increased more than proportionately with an increase in dose, from 10 mg to 20 mg. The inter-individual variability, as well as the age, weight and dose dependency are all consistent with previous findings in Japanese adults, and in Caucasian children.
10,14,15,17 The more pronounced variability in children may 
¶ geometric mean (no. patients). † † n = 7; ‡ ‡ n = 9. Group 1, age ≥1 year, weight <20 kg, esomeprazole sachet 10 mg; group 2: age 1-11 years, weight ≥20 kg, esomeprazole capsule 10 mg; group 3, age 1-11 years, weight ≥20 kg, esomeprazole capsule 20 mg; group 4, age 12-14 years, weight ≥20 kg, esomeprazole capsule 10 mg; group 5, age 12-14 years, weight ≥20 kg, esomeprazole capsule 20 mg. AUC 0-t , under the plasma concentration-time curve from time 0 to time t; AUC tau, under the plasma concentration-time curve during a dosage interval; C max , maximum plasma drug concentration; CL/F, apparent total body clearance; EM, extensive metabolizer; PK, pharmacokinetics; PM, poor metabolizer; t 1/2 , terminal elimination half-life; t max , time to reach maximum plasma concentration. Fig. 2 Plasma concentration-time curve for esomeprazole for ( ) group 1, age ≥1 year, weight <20 kg, esomeprazole sachet 10 mg; ( ) group 2, age 1-11 years, weight ≥20 kg, esomeprazole capsule 10 mg; ( ) group 3, age 1-11 years, weight ≥20 kg, esomeprazole capsule 20 mg; ( ) group 4, age 12-14 years, weight ≥20 kg, esomeprazole capsule 10 mg; ( ) group 5, age 12-14 years, weight ≥20 kg, esomeprazole capsule 20 mg. Data given as arithmetic mean AE SD. Pharmacokinetics analysis set.
be partly explained by the lower number of plasma samples in children, potential loss of substance/dose due to spitting/vomiting in some smaller children, and, further, the age-dependent maturation of the CYP liver enzymes. 17 Omeprazole and esomeprazole are metabolized mainly by the enzymes CYP3A4 and CYP2C19;
18 the latter exists in several different functional genotypes. Patients with homozygous non-functional CYP2C19 alleles are PM and have higher exposure to omeprazole, and, to a lesser extent, esomeprazole, compared with patients with homozygous-active CYP2C19 alleles (homo-EM) or heterozygous-active/non-functional CYP2C19 alleles (hetero-EM). Despite the differences in exposure due to CYP2C19 genotype, no differences have been seen in safety profile between PM and EM. [19] [20] [21] The prevalence of PM is known to be higher in East Asian populations than in Caucasian populations. 22 When patients are stratified by PM/EM, however, there are no differences in exposure to omeprazole or esomeprazole between the two geographical regions (Dr Per Lundborg, unpubl. data, 2004). In this study, the exposure in PM Japanese children was generally higher than that in EM children, even if the overlap due to inter-individual variability is large. Overall, Japanese and non-Japanese children receiving 10 mg or 20 mg esomeprazole have similar PK profiles. 14, 15 In this study, assessment of PD variables using intragastric pH monitoring was performed in a subgroup of Japanese children. Although the number of patients who consented to intragastric pH monitoring was small, a longer duration of gastric pH >4 with esomeprazole treatment was indicated, as has been seen in previous studies in Japanese adults (Dr Per Lundbord, unpubl. data, 2004) and Caucasian children. 17 The limitations of this pediatric study include the small sample size and, especially, the low number of patients evaluated for changes in symptoms, EGD, and intra-gastric pH. The relatively large pediatric population for PK evaluation and the combined evaluation of safety, clinical efficacy, PK, and PD, however, partially offset the limitations and enabled us to make reasonable assessments, supported by previous studies in Japanese adults and Caucasian children. Due to the recognized complexity of pediatric studies, it is standard for the clinical significance of pediatric data to be comprehensively assessed not only using standard statistical methods, but also with observations supported and supplemented by similar studies in adults in the same indication. 23 In conclusion, in Japanese pediatric patients aged 1-14 years with gastric acid-related disease, treatment with esomeprazole capsules or sachets at 10 mg or 20 mg once daily for 8 weeks produced no new safety concerns. The study drug was generally well tolerated and the present results are supported by the previous, well documented safety profiles in Japanese adults and Caucasian children. The PK profile involved age/weight, PM/EM, and dose-dependent exposure of esomeprazole. The efficacy was supported by the resolution of both upper GI symptoms and EGD. Esomeprazole had a similar PK, efficacy, and safety profile in Japanese children as previously seen in Caucasian children and Japanese in adults. § n = 4; ¶ n = 3; † † n = 1; ‡ ‡ n = 8. Group 1, age ≥1 year, weight <20 kg, esomeprazole sachet 10 mg; group 2: age 1-11 years, weight ≥20 kg, esomeprazole capsule 10 mg; group 3, age 1-11 years, weight ≥20 kg, esomeprazole capsule 20 mg; group 4, age 12-14 years, weight ≥20 kg, esomeprazole capsule 10 mg; group 5, age 12-14 years, weight ≥20 kg, esomeprazole capsule 20 mg. AUC tau, under the plasma concentration-time curve during a dosage interval; C max , maximum plasma drug concentration; EM, extensive metabolizer; PK, pharmacokinetics; PM, poor metabolizer.
Based on the present data, the MHLW-approved dosing for Japanese children 1-14 years is as follows: (i) reflux esophagitis, gastric or duodenal ulcer and Zollinger-Ellison syndrome: <20 kg bodyweight, 10 mg oral dose; >20 kg bodyweight, 10-20 mg oral dose; and for (ii) non-erosive esophagitis, 10 mg oral dose.
